Autres langues Indaptus Therapeutics, Inc.

Actions

INDP

US45339J1051

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 29/04/2024			Varia. 5j.	Varia. 1 janv.
2,122 ^USD	+0,56%		-13,04%	+20,56%

14/03	Les plus fortes hausses du prémarché	MT
13/03	Indaptus Therapeutics, Inc. publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting	11/04
Indaptus Therapeutics : April 2024 April 2024 Investor Presentation	08/04
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference	28/03
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting	25/03
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024	18/03
Top Premarket Gainers	14/03
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	13/03
Top Midday Gainers	04/03
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort	04/03
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial	04/03
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference	15/02
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels	08/02
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels	08/02
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology	04/01
Indaptus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/11
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	06/11
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study	06/11
Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20	06/11
Indaptus Therapeutics, Inc. Releases Interim Data from the First Cohort of Four Patients in its Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20	31/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Indaptus Therapeutics, Inc.

Actions

INDP

US45339J1051

Autres langues

Filtres